FDA Approves DALFAMPRIDINE — Accord Healthcare Inc.

# FDA Approves Generic Dalfampridine from Accord Healthcare Accord Healthcare Inc. received FDA approval for the generic version of dalfampridine, an oral treatment for multiple sclerosis, potentially intensifying competition in the walking-disability therapeutic market and creating pricing pressure for the brand-name alternative. The approval is expected to expand patient access to the mobility-enhancing therapy while reducing treatment costs across the U.S. healthcare system.